Cargando…

Impact of chronic fibrosing interstitial lung disease on healthcare use: association between fvc decline and inpatient hospitalization

BACKGROUND: Many types of interstitial lung diseases (ILDs) may transition to progressive chronic-fibrosing ILDs with rapid lung function decline and a negative survival prognosis. In real-world clinical settings, forced vital capacity (FVC) measures demonstrating progressive decline may be linked t...

Descripción completa

Detalles Bibliográficos
Autores principales: Singer, David, Chastek, Benjamin, Sargent, Andrew, Johnson, Jonathan C., Shetty, Sharash, Conoscenti, Craig, Bernstein, Elana J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10492374/
https://www.ncbi.nlm.nih.gov/pubmed/37689630
http://dx.doi.org/10.1186/s12890-023-02637-8
_version_ 1785104242292293632
author Singer, David
Chastek, Benjamin
Sargent, Andrew
Johnson, Jonathan C.
Shetty, Sharash
Conoscenti, Craig
Bernstein, Elana J.
author_facet Singer, David
Chastek, Benjamin
Sargent, Andrew
Johnson, Jonathan C.
Shetty, Sharash
Conoscenti, Craig
Bernstein, Elana J.
author_sort Singer, David
collection PubMed
description BACKGROUND: Many types of interstitial lung diseases (ILDs) may transition to progressive chronic-fibrosing ILDs with rapid lung function decline and a negative survival prognosis. In real-world clinical settings, forced vital capacity (FVC) measures demonstrating progressive decline may be linked to negative outcomes, including increased risks of costly healthcare resource utilization (HRU). Thus, we assessed the relationship between rate of decline in lung function and an increase in HRU, specifically inpatient hospitalization, among patients with chronic fibrosing ILD. METHODS: This study utilized electronic health records from 01-Oct-2015 to 31-Oct-2019. Eligible patients (≥ 18 years old) had ≥ 2 fibrosing ILD diagnosis codes, clinical activity for ≥ 15 months, and ≥ 2 FVC tests occurring 6 months apart. Patients with missing demographic data, IPF, or use of nintedanib or pirfenidone were excluded. Two groups were defined by relative change in percent of predicted FVC (FVC% pred) from baseline to 6 months: significant decline (≥ 10%) vs. marginal decline/stable FVC (decrease < 10% or increase). The primary outcome was defined as the occurrence of an inpatient hospitalization 6 months after the first FVC value. Descriptive and multivariable analysis was conducted to examine the impact of FVC decline on occurrence of inpatient hospitalization. RESULTS: The sample included 566 patients: 13% (n = 75) with significant decline and 87% (n = 491) with marginal decline/stable FVC; their mean age (SD) was 65 (13.7) years and 56% were female. Autoimmune diagnoses were observed among 40% of patients with significant decline, and 27% with marginal decline/stable FVC. The significant decline group had better lung function at baseline than the marginal/stable group. For patients with FVC% <80% at baseline, reduction of FVC% ≥10% was associated with significantly increased odds of an inpatient hospitalization (odds ratio [OR] 2.85; confidence interval [CI] 1.17, 6.94 [p = 0.021]). CONCLUSION: Decline in FVC% ≥10% was associated with increased odds of inpatient hospitalization among patients with reduced lung function at baseline. These findings support the importance of preserving lung function among patients with fibrosing ILD. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12890-023-02637-8.
format Online
Article
Text
id pubmed-10492374
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-104923742023-09-10 Impact of chronic fibrosing interstitial lung disease on healthcare use: association between fvc decline and inpatient hospitalization Singer, David Chastek, Benjamin Sargent, Andrew Johnson, Jonathan C. Shetty, Sharash Conoscenti, Craig Bernstein, Elana J. BMC Pulm Med Research BACKGROUND: Many types of interstitial lung diseases (ILDs) may transition to progressive chronic-fibrosing ILDs with rapid lung function decline and a negative survival prognosis. In real-world clinical settings, forced vital capacity (FVC) measures demonstrating progressive decline may be linked to negative outcomes, including increased risks of costly healthcare resource utilization (HRU). Thus, we assessed the relationship between rate of decline in lung function and an increase in HRU, specifically inpatient hospitalization, among patients with chronic fibrosing ILD. METHODS: This study utilized electronic health records from 01-Oct-2015 to 31-Oct-2019. Eligible patients (≥ 18 years old) had ≥ 2 fibrosing ILD diagnosis codes, clinical activity for ≥ 15 months, and ≥ 2 FVC tests occurring 6 months apart. Patients with missing demographic data, IPF, or use of nintedanib or pirfenidone were excluded. Two groups were defined by relative change in percent of predicted FVC (FVC% pred) from baseline to 6 months: significant decline (≥ 10%) vs. marginal decline/stable FVC (decrease < 10% or increase). The primary outcome was defined as the occurrence of an inpatient hospitalization 6 months after the first FVC value. Descriptive and multivariable analysis was conducted to examine the impact of FVC decline on occurrence of inpatient hospitalization. RESULTS: The sample included 566 patients: 13% (n = 75) with significant decline and 87% (n = 491) with marginal decline/stable FVC; their mean age (SD) was 65 (13.7) years and 56% were female. Autoimmune diagnoses were observed among 40% of patients with significant decline, and 27% with marginal decline/stable FVC. The significant decline group had better lung function at baseline than the marginal/stable group. For patients with FVC% <80% at baseline, reduction of FVC% ≥10% was associated with significantly increased odds of an inpatient hospitalization (odds ratio [OR] 2.85; confidence interval [CI] 1.17, 6.94 [p = 0.021]). CONCLUSION: Decline in FVC% ≥10% was associated with increased odds of inpatient hospitalization among patients with reduced lung function at baseline. These findings support the importance of preserving lung function among patients with fibrosing ILD. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12890-023-02637-8. BioMed Central 2023-09-09 /pmc/articles/PMC10492374/ /pubmed/37689630 http://dx.doi.org/10.1186/s12890-023-02637-8 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Singer, David
Chastek, Benjamin
Sargent, Andrew
Johnson, Jonathan C.
Shetty, Sharash
Conoscenti, Craig
Bernstein, Elana J.
Impact of chronic fibrosing interstitial lung disease on healthcare use: association between fvc decline and inpatient hospitalization
title Impact of chronic fibrosing interstitial lung disease on healthcare use: association between fvc decline and inpatient hospitalization
title_full Impact of chronic fibrosing interstitial lung disease on healthcare use: association between fvc decline and inpatient hospitalization
title_fullStr Impact of chronic fibrosing interstitial lung disease on healthcare use: association between fvc decline and inpatient hospitalization
title_full_unstemmed Impact of chronic fibrosing interstitial lung disease on healthcare use: association between fvc decline and inpatient hospitalization
title_short Impact of chronic fibrosing interstitial lung disease on healthcare use: association between fvc decline and inpatient hospitalization
title_sort impact of chronic fibrosing interstitial lung disease on healthcare use: association between fvc decline and inpatient hospitalization
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10492374/
https://www.ncbi.nlm.nih.gov/pubmed/37689630
http://dx.doi.org/10.1186/s12890-023-02637-8
work_keys_str_mv AT singerdavid impactofchronicfibrosinginterstitiallungdiseaseonhealthcareuseassociationbetweenfvcdeclineandinpatienthospitalization
AT chastekbenjamin impactofchronicfibrosinginterstitiallungdiseaseonhealthcareuseassociationbetweenfvcdeclineandinpatienthospitalization
AT sargentandrew impactofchronicfibrosinginterstitiallungdiseaseonhealthcareuseassociationbetweenfvcdeclineandinpatienthospitalization
AT johnsonjonathanc impactofchronicfibrosinginterstitiallungdiseaseonhealthcareuseassociationbetweenfvcdeclineandinpatienthospitalization
AT shettysharash impactofchronicfibrosinginterstitiallungdiseaseonhealthcareuseassociationbetweenfvcdeclineandinpatienthospitalization
AT conoscenticraig impactofchronicfibrosinginterstitiallungdiseaseonhealthcareuseassociationbetweenfvcdeclineandinpatienthospitalization
AT bernsteinelanaj impactofchronicfibrosinginterstitiallungdiseaseonhealthcareuseassociationbetweenfvcdeclineandinpatienthospitalization